![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, December 18, 2018 9:39:14 AM
LOS ANGELES, CA, Dec. 18, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB:ENDV) ("Endonovo" or the "Company"), a commercial-stage developer of non-invasive Electroceutical™ therapies brand, today announced the allowance for the patent application entitled DEVICES AND METHOD FOR TREATMENT OF DEGENERATIVE JOINT DISEASES WITH ELECTROMAGNETIC FIELDS by the U.S. Patent and Trademark Office. Endonovo will be including this technology under its WOUNDPULSE™brand.
Alan Collier, CEO of Endonovo Therapeutics, stated, "This Notice of Allowance highlights treatments with SofPulse™ brand, which allows patients to better manage pain without the adverse side effects of narcotics and anti-inflammatory medication. SofPulse™ brand reduces pain and edema and thereby decreases the requirement for medication post-surgery. With less pain and less medication, patients can stimulate the body's natural response to healing much quicker."
"With the opioid epidemic being so far-reaching, we believe SofPulse™ brand is an alternative that can be widely used. Our ongoing efforts have been very positive when speaking to clinicians and patients. I am pleased with our accomplishments throughout 2018 and believe in having secured Intellectual Property protection for WOUNDPULSE™ brand we can implement a strategic sales and marketing campaign. We continue to expand our relationships with our current distributors and in discussions with prospective partners. We are also building an internal sales team that can focus its efforts on hospitals, cosmetic surgery centers, physicians and surgeons. As such, we are modifying some old marketing material and creating new sales and marketing material which now can include the WOUNDPULSE™ brand.
For additional information visit www.sofpulse.com
https://www.nasdaq.com/press-release/endonovo-therapeutics-announces-receipt-of-notice-of-allowance-from-the-united-states-patent-and-20181218-00591
Recent ENDV News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 02/02/2024 10:23:02 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/03/2024 10:30:14 PM
- Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 12/29/2023 08:20:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/04/2023 02:08:41 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 05:21:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 10:03:32 AM
- Form 1-A/A - Offering Statement [Regulation A]: [Amend] • Edgar (US Regulatory) • 08/25/2023 11:04:33 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/21/2023 09:16:04 PM
FEATURED Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM